<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CENTANY- mupirocin ointment </strong><br>OrthoNeutrogena, Division of Ortho-McNeil Pharmaceutical, Inc.<br></p></div>
<h1>CENTANY<span class="Sup">™</span><br>(mupirocin ointment),2%</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-2"></a><p></p>
<p class="First">OrthoNeutrogena</p>
<p>Rx only       For Dermatologic Use</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each gram of Centany (mupirocin ointment),2% contains 20 mg mupirocin in a soft white ointment base consisting of castor oil, oleyl alcohol, hard fat (Softisan<span class="Sup">®</span> 378) and propylene glycol monostearate. Mupirocin is a naturally occurring antibiotic. The chemical name is (E)-(2S,3<span class="Italics">R</span>,4<span class="Italics">R</span>,5<span class="Italics">S</span>)-5-[(2<span class="Italics">S</span>,3<span class="Italics">S</span>,4<span class="Italics">S</span>,5<span class="Italics">S</span>)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2 <span class="Italics">H</span>-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid. The molecular formula of mupirocin is C<span class="Sub">26</span>H<span class="Sub">44</span>O<span class="Sub">9</span> and the molecular weight is 500.63. The chemical structure is:</p>
<div class="Figure">
<a name="f1"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3defca-06d5-49ac-8a27-be5c4e9304d1&amp;name=centany-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following the application of Centany (mupirocin ointment),2% to a 400 cm<span class="Sup">2</span> area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1.25% (0.2% to 3.0%) of the administered dose of mupirocin. The monic acid concentration in urine collected at specified intervals for 24 hrs on Day 7 ranged from &lt;0.050 to 0.637 μg/mL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-4.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Mupirocin is an antibacterial agent produced by fermentation using the organism <span class="Italics">Pseudomonas fluorescens</span>. Its spectrum of activity includes gram-positive bacteria. It is also active, <span class="Italics">in vitro</span> only, against certain gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of action, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents.</p>
<p>When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase or the acquisition, by genetic transfer, of a plasmid mediating a new isoleucyl-tRNA synthetase.  High-level plasmid-mediated resistance (MIC &gt; 500 mcg/mL) has been reported in increasing numbers of isolates of <span class="Italics">Staphylococcus aureus</span> and with higher frequency in coagulase-negative staphylococci. Methicillin resistance and mupirocin resistance commonly occur together in <span class="Italics">Staphylococcus aureus</span> and coagulase negative staphylococci.</p>
<p>Mupirocin is bactericidal at concentrations achieved by topical administration. However, the minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC). In addition, mupirocin is highly protein bound (&gt;97%), and the effect of <span class="product-label-link" type="condition" conceptid="4343235" conceptname="Wound discharge">wound secretions</span> on the MICs of mupirocin has not been determined.</p>
<p>Mupirocin has been shown to be active against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span>, both <span class="Italics">in vitro</span> and in clinical studies. (See <span class="Bold"><a href="#s5">INDICATIONS AND USAGE.</a>)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Centany (mupirocin ointment),2% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> due to: <span class="Italics">Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Centany (mupirocin ointment),2% is not for ophthalmic use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">If a reaction suggesting sensitivity or chemical irritation should occur with the use of Centany (mupirocin ointment),2%, treatment should be discontinued and appropriate alternative therapy for the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> instituted.</p>
<p>As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Centany (mupirocin ointment),2% is not formulated for use on mucosal surfaces. Centany (mupirocin ointment),2% is not intended for nasal use.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="s9"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Use this medication only as directed by your healthcare provider. It is for external use only. Avoid contact with the eyes. The medication should be stopped and your healthcare practitioner contacted if irritation, severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs. If <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> has not improved in 3 to 5 days, contact your healthcare practitioner.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s10"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> The effect of the concurrent application of Centany (mupirocin ointment),2% and other drug products is unknown.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term studies in animals to evaluate carcinogenic potential of mupirocin have not been conducted.</p>
<p>Results of the following studies performed with mupirocin calcium or mupirocin sodium <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> reversion test (Ames), <span class="Italics">Escherichia coli</span> mutation assay, metaphase analysis of human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and bone marrow micronuclei assay in mice.</p>
<p>Reproduction studies were performed in male and female rats with mupirocin administered subcutaneously at doses up to 14 times the human topical dose (approximately 60 mg mupirocin/ day) on a mg/m<span class="Sup">2</span> basis and revealed neither evidence of impaired fertility nor impaired reproductive performance attributable to mupirocin.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-8.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s13"></a><a name="section-8.4.1"></a><p></p>
<h3>Teratogenic Effects.</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-8.4.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B:</span> Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) on a mg/m<span class="Sup">2</span> basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s15"></a><a name="section-8.5"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Centany (mupirocin ointment),2% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s16"></a><a name="section-8.6"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> The safety and effectiveness of Centany (mupirocin ointment),2% have been established in the age range of 2 months to 16 years. Use of Centany (mupirocin ointment),2% in these age groups is supported by evidence from adequate and well-controlled studies of Centany (mupirocin ointment),2% in <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> in pediatric patients studied as a part of the pivotal clinical trials. (See <span class="Bold"><a href="#s19">CLINICAL STUDIES.</a>)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s17"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following local adverse reactions have been reported in connection with the use of Centany (mupirocin ointment),2%; <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, each in 1% of patients; <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> and <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, each in 0.7% of patients; and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, each in 0.3% of patients.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s18"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">A small amount of Centany (mupirocin ointment),2% should be applied to the affected area three times daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s19"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The efficacy of topical Centany (mupirocin ointment),2% in <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> was tested in one study. Patients with <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> were randomized to receive either Centany (mupirocin ointment), 2% or Bactroban<span class="Sup">®</span> Ointment (mupirocin ointment, 2%) t.i.d. for 7 days. Clinical efficacy rates at the follow-up visit (one week after end of therapy) in the evaluable populations (adults and pediatric patients included) were 94% for Centany (mupirocin ointment), 2% (n=233) and 95% for Bactroban<span class="Sup">®</span> Ointment (mupirocin ointment, 2%) (n=242). Pathogen eradication rates at follow-up for both medications were 98%.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-11.1"></a><p></p>
<h2>Pediatrics</h2>
<p class="First">There were 413 pediatric patients aged 2 months to 15 years in the clinical study described above. Clinical efficacy rates at follow-up in the evaluable populations were 93% for Centany (mupirocin ointment), 2% (n=199) and 95% for Bactroban<span class="Sup">®</span> Ointment (mupirocin ointment, 2%) (n=214).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s21"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Centany (mupirocin ointment),2% is supplied in 15 gram (NDC 0062-1610-01) and 30 gram (NDC 0062-1610-03) tubes.</p>
<p>Store at controlled room temperature 20° to 25°C (68° to 77°F).</p>
<p>OrthoNeutrogena</p>
<p>Distributed by: OrthoNeutrogena, Division of Ortho-McNeil Pharmaceutical, Inc.<br>Skillman, New Jersey 08558<br>©OMP 2004<br>Rev: April 2004<br>Printed in USA<br>635-10-686-3<br>U.S. Patent No. 6,013,657</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENTANY 		
					</strong><br><span class="contentTableReg">mupirocin ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0062-1610</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>mupirocin</strong> (mupirocin) </td>
<td class="formItem"></td>
<td class="formItem">20 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Castor oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Oleyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hard fat (Softisan 378)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Propylene glycol monostearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0062-1610-01</td>
<td class="formItem">15 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0062-1610-03</td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>OrthoNeutrogena, Division of Ortho-McNeil Pharmaceutical, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2A608591-E6B9-F6BE-9870-BFB5DFEE47ED</div>
<div>Set id: ae3defca-06d5-49ac-8a27-be5c4e9304d1</div>
<div>Version: 1</div>
<div>Effective Time: 20070213</div>
</div>
</div> <div class="DistributorName">OrthoNeutrogena, Division of Ortho-McNeil Pharmaceutical, Inc.</div></p>
</body></html>
